Optimal Management of Hypertension in Patients with Cardiovascular Disease

Primary Recommendation Based on Cardiovascular Disease Type

• The European Society of Cardiology recommends ACE inhibitors as the preferred initial therapy for patients with recent myocardial infarction or systolic heart failure, as they reduce recurrent myocardial infarction, death, and heart failure hospitalizations 1, 2
• Beta-blockers should be added to ACE inhibitors in post-MI patients for additional mortality benefit, according to the European Heart Journal 2
• The European Heart Journal suggests that calcium channel blockers should be avoided in patients with congestive heart failure unless needed specifically for blood pressure control or anginal symptoms 1, 2
• Dihydropyridine calcium channel blockers, such as amlodipine, can be added if hypertension persists after ACE inhibitors, diuretics, and beta-blockers, particularly with concomitant angina, as recommended by the European Heart Journal 1

Comparative Effectiveness Evidence

• The American Diabetes Association notes that ACE inhibitors demonstrate lower combined cardiovascular disease rates compared to calcium channel blockers in high-risk patients 3, 4
• The European Heart Journal states that ACE inhibitors reduce heart failure events by 13-16% compared to calcium channel blockers (RR 0.87, 95% CI 0.78-0.96) 1, 2

Optimal Combination Therapy Strategy

• The American College of Cardiology recommends ACE inhibitor or ARB plus CCB as a preferred initial combination in most hypertensive patients 6
• The Journal of the American College of Cardiology suggests that ACE inhibitor plus thiazide diuretic is effective and reduces cardiovascular events 6, 7
• The Diabetes Care journal notes that the ADVANCE trial showed perindopril plus indapamide significantly reduced combined microvascular and macrovascular outcomes 3, 4

Blood Pressure Targets in Cardiovascular Disease

• The American College of Cardiology and American Heart Association recommend aiming for blood pressure around 130/80 mmHg or less in patients with chronic coronary heart disease 6
• The European Heart Journal states that beneficial effects are demonstrated even when initial blood pressure is <140/90 mmHg 1, 2

Critical Caveats and Common Pitfalls

• The European Heart Journal warns that non-dihydropyridine CCBs should be avoided in patients with systolic heart failure unless specifically needed for blood pressure or angina control 1, 2
• The Journal of the American College of Cardiology advises against dual RAAS blockade (ACE inhibitor plus ARB), which increases adverse events without improving outcomes 6, 9

Practical Implementation Algorithm

• The American College of Cardiology recommends starting ACE inhibitor plus beta-blocker for post-MI or systolic heart failure patients 6
• The European Heart Journal suggests that either ACE inhibitor or CCB is acceptable for chronic stable CAD without heart failure 1, 2
• The Journal of the American College of Cardiology recommends starting combination therapy with ACE inhibitor plus CCB or ACE inhibitor plus thiazide if blood pressure is >20/10 mmHg above target 6